135 related articles for article (PubMed ID: 15998587)
1. Serum levels of IGF-1 and IGFBP-3 during adjuvant chemotherapy for primary breast cancer.
Fürstenberger G; Senn E; Morant R; Bolliger B; Senn HJ
Breast; 2006 Feb; 15(1):64-8. PubMed ID: 15998587
[TBL] [Abstract][Full Text] [Related]
2. Serum IGF-I, IGFBP-3, and matrix metalloproteinase-7 levels and acquired chemo-resistance in advanced colorectal cancer.
Gallego R; Codony-Servat J; García-Albéniz X; Carcereny E; Longarón R; Oliveras A; Tosca M; Augé JM; Gascón P; Maurel J
Endocr Relat Cancer; 2009 Mar; 16(1):311-7. PubMed ID: 19109398
[TBL] [Abstract][Full Text] [Related]
3. Effect of raloxifene on insulin-like growth factor-I, insulin-like growth factor binding protein-3, and leptin in premenopausal women at high risk for developing breast cancer.
Eng-Wong J; Hursting SD; Venzon D; Perkins SN; Zujewski JA
Cancer Epidemiol Biomarkers Prev; 2003 Dec; 12(12):1468-73. PubMed ID: 14693739
[TBL] [Abstract][Full Text] [Related]
4. Insulin-like growth factor-I, its binding proteins (IGFBP-1 and IGFBP-3), and growth hormone and breast cancer risk in The Nurses Health Study II.
Schernhammer ES; Holly JM; Hunter DJ; Pollak MN; Hankinson SE
Endocr Relat Cancer; 2006 Jun; 13(2):583-92. PubMed ID: 16728584
[TBL] [Abstract][Full Text] [Related]
5. Relationships between plasma insulin-like growth factor-I and insulin-like growth factor binding protein-3 and second breast cancer risk in a prevention trial of fenretinide.
Decensi A; Veronesi U; Miceli R; Johansson H; Mariani L; Camerini T; Di Mauro MG; Cavadini E; De Palo G; Costa A; Perloff M; Malone WF; Formelli F
Clin Cancer Res; 2003 Oct; 9(13):4722-9. PubMed ID: 14581342
[TBL] [Abstract][Full Text] [Related]
6. Quality of life in women with breast cancer during the first year after random assignment to adjuvant treatment with marrow-supported high-dose chemotherapy with cyclophosphamide, thiotepa, and carboplatin or tailored therapy with Fluorouracil, epirubicin, and cyclophosphamide: Scandinavian Breast Group Study 9401.
Brandberg Y; Michelson H; Nilsson B; Bolund C; Erikstein B; Hietanen P; Kaasa S; Nilsson J; Wiklund T; Wilking N; Bergh J;
J Clin Oncol; 2003 Oct; 21(19):3659-64. PubMed ID: 14512398
[TBL] [Abstract][Full Text] [Related]
7. Effect of raloxifene on IGF-I and IGFBP-3 in postmenopausal women with breast cancer.
Torrisi R; Baglietto L; Johansson H; Veronesi G; Bonanni B; Guerrieri-Gonzaga A; Ballardini B; Decensi A
Br J Cancer; 2001 Dec; 85(12):1838-41. PubMed ID: 11747323
[TBL] [Abstract][Full Text] [Related]
8. Analysis of insulin like growth factor 1 and insulin like growth factor binding protein 3 levels in bronchoalveolar lavage fluid and serum of patients with lung cancer.
Unsal E; Köksal D; Yurdakul AS; Atikcan S; Cinaz P
Respir Med; 2005 May; 99(5):559-65. PubMed ID: 15823452
[TBL] [Abstract][Full Text] [Related]
9. Effects of tamoxifen on insulin-like growth factors, IGF binding proteins and IGFBP-3 proteolysis in breast cancer patients.
Grønbaek H; Tanos V; Meirow D; Peretz T; Raz I; Flyvbjerg A
Anticancer Res; 2003; 23(3C):2815-20. PubMed ID: 12926118
[TBL] [Abstract][Full Text] [Related]
10. Putative role of serum insulin-like growth factor-1 (IGF-1) and IGF binding protein-3 (IGFBP-3) levels in the development of prostate cancer in Arab men.
Kehinde EO; Akanji AO; Mojiminiyi OA; Bashir AA; Daar AS; Varghese R
Prostate Cancer Prostatic Dis; 2005; 8(1):84-90. PubMed ID: 15775992
[TBL] [Abstract][Full Text] [Related]
11. [The feasibility of FEC (75) as adjuvant chemotherapy for Japanese breast cancer patients].
Kim SJ; Taguchi T; Miyoshi Y; Tanji Y; Tamaki Y; Noguchi S
Gan To Kagaku Ryoho; 2005 Nov; 32(12):1919-23. PubMed ID: 16282727
[TBL] [Abstract][Full Text] [Related]
12. Circulating insulin-like growth factor-I and binding protein-3 and the risk of breast cancer.
Baglietto L; English DR; Hopper JL; Morris HA; Tilley WD; Giles GG
Cancer Epidemiol Biomarkers Prev; 2007 Apr; 16(4):763-8. PubMed ID: 17416768
[TBL] [Abstract][Full Text] [Related]
13. Genetic variation in the growth hormone synthesis pathway in relation to circulating insulin-like growth factor-I, insulin-like growth factor binding protein-3, and breast cancer risk: results from the European prospective investigation into cancer and nutrition study.
Canzian F; McKay JD; Cleveland RJ; Dossus L; Biessy C; Boillot C; Rinaldi S; Llewellyn M; Chajès V; Clavel-Chapelon F; Téhard B; Chang-Claude J; Linseisen J; Lahmann PH; Pischon T; Trichopoulos D; Trichopoulou A; Zilis D; Palli D; Tumino R; Vineis P; Berrino F; Bueno-de-Mesquita HB; van Gils CH; Peeters PH; Pera G; Barricarte A; Chirlaque MD; Quirós JR; Larrañaga N; Martínez-García C; Allen NE; Key TJ; Bingham SA; Khaw KT; Slimani N; Norat T; Riboli E; Kaaks R
Cancer Epidemiol Biomarkers Prev; 2005 Oct; 14(10):2316-25. PubMed ID: 16214911
[TBL] [Abstract][Full Text] [Related]
14. Specimen processing time and measurement of total insulin-like growth factor-I (IGF-I), free IGF-I, and IGF binding protein-3 (IGFBP-3).
Harris TG; Strickler HD; Yu H; Pollak MN; Monrad ES; Travin MI; Xue X; Rohan TE; Kaplan RC
Growth Horm IGF Res; 2006 Apr; 16(2):86-92. PubMed ID: 16530441
[TBL] [Abstract][Full Text] [Related]
15. Lack of TIMP-1 tumour cell immunoreactivity predicts effect of adjuvant anthracycline-based chemotherapy in patients (n=647) with primary breast cancer. A Danish Breast Cancer Cooperative Group Study.
Willemoe GL; Hertel PB; Bartels A; Jensen MB; Balslev E; Rasmussen BB; Mouridsen H; Ejlertsen B; Brünner N
Eur J Cancer; 2009 Sep; 45(14):2528-36. PubMed ID: 19535243
[TBL] [Abstract][Full Text] [Related]
16. Long-term effects of fenretinide, a retinoic acid derivative, on the insulin-like growth factor system in women with early breast cancer.
Decensi A; Johansson H; Miceli R; Mariani L; Camerini T; Cavadini E; Di Mauro MG; Barreca A; Gonzaga AG; Diani S; Sandri MT; De Palo G; Formelli F
Cancer Epidemiol Biomarkers Prev; 2001 Oct; 10(10):1047-53. PubMed ID: 11588130
[TBL] [Abstract][Full Text] [Related]
17. Elevated serum insulin-like growth factor (IGF-1) and IGF binding protein-3 levels in patients with systemic sclerosis: possible role in development of fibrosis.
Hamaguchi Y; Fujimoto M; Matsushita T; Hasegawa M; Takehara K; Sato S
J Rheumatol; 2008 Dec; 35(12):2363-71. PubMed ID: 19004037
[TBL] [Abstract][Full Text] [Related]
18. The potential risk of neoadjuvant chemotherapy in breast cancer patients--results from a prospective randomized trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-07).
Taucher S; Steger GG; Jakesz R; Tausch C; Wette V; Schippinger W; Kwasny W; Reiner G; Greil R; Dubsky P; Poestlberger S; Tschmelitsch J; Samonigg H; Gnant M;
Breast Cancer Res Treat; 2008 Nov; 112(2):309-16. PubMed ID: 18080748
[TBL] [Abstract][Full Text] [Related]
19. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and breast cancer risk: eight years on.
Renehan AG; Harvie M; Howell A
Endocr Relat Cancer; 2006 Jun; 13(2):273-8. PubMed ID: 16728563
[TBL] [Abstract][Full Text] [Related]
20. Inflammatory breast cancer outcome with epirubicin-based induction and maintenance chemotherapy: ten-year results from the French Adjuvant Study Group GETIS 02 Trial.
Veyret C; Levy C; Chollet P; Merrouche Y; Roche H; Kerbrat P; Fumoleau P; Fargeot P; Clavere P; Chevallier B
Cancer; 2006 Dec; 107(11):2535-44. PubMed ID: 17054108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
